Pancreatic Cancer Research

ResearcherHarbin Medical UniversityActive in the last 2 years

Yanqiao Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5203-3814; OpenAlex author ID A5111560900. Sources: OpenAlex.

Their work

Papers
3 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
12
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 3

  1. NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial. First author DOI 10.1038/s41467-026-68409-0↗
  2. Ginkgolide B enhances gemcitabine sensitivity in pancreatic cancer cell lines via inhibiting PAFR/NF-кB pathway. Last author DOI 10.1016/j.biopha.2018.10.084↗
  3. Naringenin decreases invasiveness and metastasis by inhibiting TGF-β-induced epithelial to mesenchymal transition in pancreatic cancer cells. Co-author DOI 10.1371/journal.pone.0050956↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiuchao Wang · 1 shared paper, 2026 · strength 0.19
  2. Song Gao · 1 shared paper, 2026 · strength 0.19
  3. Chuntao Gao · 1 shared paper, 2026 · strength 0.19
  4. Tiansuo Zhao · 1 shared paper, 2026 · strength 0.19
  5. Chengyou Du · 1 shared paper, 2026 · strength 0.19
  6. Zhihua Li · 1 shared paper, 2026 · strength 0.19
  7. Xiujuan Qu · 1 shared paper, 2026 · strength 0.19
  8. Jihui Hao · 1 shared paper, 2026 · strength 0.19
  9. Rui Liu · 1 shared paper, 2026 · strength 0.19
  10. Xianglin Yuan · 1 shared paper, 2026 · strength 0.19
  11. Changjie Lou · 2 shared papers, 2012–2019 · strength 0.15
  12. Wei Ping Liang · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.